KR101957849B1 - Composition for promoting hair growth or restoration and anti-inflammatory composition - Google Patents

Abstract

In this specification, compositions for promoting hair growth or hair growth and compositions for anti-inflammation are disclosed. The composition may be a pharmaceutical composition, a cosmetic composition or a food composition, and may be selected from the group consisting of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamaponin D, (Assamsaponin D) and Thia saffronin C1 (Theasaponin C1).

Description

TECHNICAL FIELD [0001] The present invention relates to a composition for promoting hair growth or hair growth and for anti-inflammation,

In this specification, compositions for promoting hair growth or hair growth and compositions for anti-inflammation are disclosed.

The causes of hair loss include male hypothyroidism, excess sebaceous glands, poor blood circulation, peroxidation, hypofunction of the scalp, genetic factors, aging, and stress. Along with the increase in social stress, the hair loss population is gradually increasing due to westernized eating habits such as environmental pollution and instant food, frequent perm and dyeing. The cycle of hair consists of anagen which grows hair, catagen which is the period of termination of growth and reduction of the size of the moles, taloge which is the period when the papilla stops its activity and keeps its hair on the scalp, Or a generator that generates new hair to depilate old hair.

The Anagen Stage (2-7 years) is the period of hair growth, divided into hair growth stages where the hair is going to go out from the hair to the blanket and the stage where the hard keratin is made inside the hair follicle. Hair continues to self-grow until the retrogressive. Catagen Stage (2 to 3 weeks) is the period when the metabolic process is slowed down at the end of the growing season, maintaining the shape of the hair, and does not produce keratin at this stage. Degenerators account for 1% of total hair. At this time, the mothers shrink and divide into the dermal papilla, surrounded by the hair follicles and go upwards, and cell division is stopped. The Talogen Stage (3 months) shrinks the papillary, the hair follicles shrink gradually, and the hair follicles are pushed upwards and fall out. The lifespan of the hair until the next stage of growth begins is 3 to 4 months.

A person with normal hair has a lot of hair growing, whereas a person with alopecia (Alopecia) has a lot of hair in a resting state, so that a visible hair loss phenomenon appears. As hair loss progresses, the period of growth is shortened and hair becomes smaller and smaller. Therefore, in order to treat hair loss, it is important to allow the hair follicle in a resting state to rapidly grow and to shorten the growth period.

Male alopecia are caused by testosterone, a testosterone that is converted to a more powerful hormone, Dihydrotestosterone (DHT), by an enzyme called 5α-reductase. Hormone acts on the hair follicle to induce the hair follicle from the growing stage to the regenerator stage to cause hair loss. Therefore, a method of inhibiting the production of DHT by 5 alpha-reductase in order to treat male alopecia is mainly used.

Female alopecia are caused mainly by a decrease in the amount of estrogen after menopause. Minoxidil and estrogen are mainly used as therapeutic agents for female alopecia.

Alopecia areata is caused by autoimmune diseases, mental stress, genetic predisposition. These alopecia areata are fundamentally different from those of androgenetic alopecia, and different methods of treatment are used, such as a method of treating corticosteroids, minoxidil being applied to the affected part or artificially induced to the affected part.

However, in the case of preparations such as minoxidil and trichosaccharide, which have been known to prevent hair loss and promote hair growth and to induce hair growth, there is a lack of clear efficacy and human stability, skin irritation There is an urgent need to develop a composition having safety and efficacy.

Vaso-active amines, Baso-active polypeptides, and other mediators are the mediators responsible for inflammation, and vasoactive amines include histamine and histamine, which are secreted from mast cells. And retinin, which act mainly to enhance vasodilation and permeability. In addition, the vasoactive polypeptides include kinin, plasmin, and complement, which act as vasoconstrictors. In addition, lymphokines such as interleukin-6 (IL-6) Arachidonic acid and the like are responsible for the inflammatory reaction.

The arachidonic acid produced by the phospholipase activated by physical and chemical stimuli is converted to the inflammatory response mediator prostaglandin through the two pathways of cyclooxygenase (COX) or lipooxygenase, It is metabolized by leukotriene and mediates various inflammatory responses (Thomas, R., Rev. Physiol. Biochem. Pharmacol., 100, 1984, published patent 10-2008-0020853).

Korean Patent No. 10-1274029

In one aspect, the present disclosure relates to a pharmaceutical composition comprising a compound selected from the group consisting of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, (Theasaponin C1) as an active ingredient. The present invention also provides a composition for promoting hair growth or hair growth.

In another aspect, the present disclosure relates to a pharmaceutical composition comprising a compound selected from the group consisting of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, (Theasaponin C1) as an active ingredient. The present invention also provides a composition for anti-inflammation comprising the same.

[Chemical Formula]

In one aspect, the techniques disclosed herein are directed to a method of inhibiting the production of a compound of the formula (I), wherein the compound is selected from the group consisting of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Wherein the composition comprises at least one selected from the group consisting of Assamsaponin D and Thaapaponin C1 as an active ingredient.

In other respects, the techniques disclosed herein are directed to the compounds of formula (I), wherein said compound is selected from the group consisting of the compounds selected from the group consisting of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, And at least one selected from the group consisting of Assamsaponin D and Thaasaponin C1 as an active ingredient.

According to one exemplary embodiment, the active ingredient may be isolated from Camellia Seed extract.

According to one exemplary embodiment, the composition may be to proliferate hair follicular dermal papilla cells.

According to one exemplary embodiment, the composition may be one that inhibits PGE2, IL-6 or IL-8 production.

According to one exemplary embodiment, the active ingredient may be included in an amount of 0.001 to 20% by weight based on the total weight of the composition.

According to one exemplary embodiment, the composition may be a pharmaceutical composition.

According to one exemplary embodiment, the composition may be a cosmetic composition.

According to one exemplary embodiment, the composition may be a food composition.

In one aspect, the techniques disclosed herein are directed to the use of a compound of formula (I), wherein the compound is selected from the group consisting of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, And thaazaponin C1 (theasaponin C1) as an active ingredient. The present invention also provides a composition for promoting hair growth or hair growth.

In another aspect, the techniques disclosed herein are directed to the use of a compound selected from the group consisting of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, And thaasaponin C1 (theasaponin C1) as an active ingredient.

In another aspect, the technology disclosed in this specification has the effect of providing a pharmaceutical composition, a cosmetic composition, and a food composition for promoting hair growth or hair growth, which has no side effects and is excellent in stability by including a plant natural substance as an effective ingredient.

Hereinafter, the present invention will be described in detail.

[Chemical Formula]

In one aspect, the techniques disclosed herein are directed to a method of inhibiting the production of a compound of the formula (I), wherein the compound is selected from the group consisting of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Wherein the composition comprises at least one selected from the group consisting of Assamsaponin D and Thaapaponin C1 as an active ingredient.

In other respects, the techniques disclosed herein are directed to the compounds of formula (I), wherein said compound is selected from the group consisting of the compounds selected from the group consisting of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, And at least one selected from the group consisting of Assamsaponin D and Thaasaponin C1 as an active ingredient.

According to one exemplary embodiment, the active ingredient may be isolated from Camellia Seed extract. The saponins separated from the camellia seed extract, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D or Theasaponin C1 are obtained by extracting saponin from camelliace seeds using water or an organic solvent; And separating Asssaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D and Theasaponin C1 from the extract.

The step of obtaining the saponin-containing extract from the camelliace can be appropriately applied, modified or applied by a person skilled in the art by appropriately selecting from the method of producing an extract used in the technical field.

According to one exemplary embodiment, the organic solvent may be at least one organic solvent selected from the group consisting of ethanol, methanol, butanol, ether, ethyl acetate and chloroform or a mixture thereof with water, in one aspect 50% ethanol.

Further, according to an exemplary embodiment, fractionation using a solvent is followed by concentration under reduced pressure to remove the solvent to obtain a crude product, and then the obtained crude product is purified by C18 column chromatography (acetonitrile: water = 8: 1 to 4: 1) to obtain Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, Theasaponin C1.

According to one exemplary embodiment, the composition may be to proliferate hair follicular dermal papilla cells. The composition has the effect of activating keratinocyte cells by proliferation of hair follicular dermal papilla cells, promoting the expression of hair growth factor VEGF and promoting hair generation. In addition, the composition of the present invention has the effect of promoting hair growth and preventing or improving hair loss by shortening the period of transition from the resting period to the growing period in the hair growing period.

According to one exemplary embodiment, the composition may be one that inhibits PGE2, IL-6 or IL-8 production.

According to one exemplary embodiment, the active ingredient may be included in an amount of 0.001 to 20% by weight based on the total weight of the composition. According to another embodiment, the active ingredient may be included in an amount of 0.01 to 15% by weight, 0.01 to 10% by weight, or 0.1 to 5% by weight based on the total weight of the composition.

In one aspect, the active ingredient contained in the compositions disclosed herein may comprise from 0.001% by weight to 0.01% by weight, from 0.1% by weight or more, or from 1.0% by weight or more, based on the total weight of the composition, 20 wt% or less, 15 wt% or less, 10 wt% or less, or 5 wt% or less. The content is not particularly limited, but it is 0.001% by weight or more, so that the hair growth, hair growth and anti-inflammatory effect of the composition are excellent. When the content is 20% by weight or less, safety or formability is easy to manufacture and exhibits excellent efficacy without side effects .

According to one exemplary embodiment, the composition may be a pharmaceutical composition.

The pharmaceutical composition may further contain, in addition to the active ingredients disclosed herein, preservatives, stabilizers, hydrating agents or emulsifying accelerators, pharmaceutical adjuvants such as salts and / or buffers for controlling osmotic pressure, and other therapeutically useful substances, May be formulated into various oral or parenteral dosage forms according to conventional methods.

Examples of the oral administration agent include tablets, pills, hard and soft capsules, liquids, suspensions, emulsions, syrups, powders, powders, granules, granules and pellets, , Diluents (such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine), lubricants (such as silica, talc, stearic acid and magnesium or calcium salts thereof and polyethylene glycols) . The tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally mixed with starch, agar, alginic acid or its sodium salt Such as disintegrants, absorbents, coloring agents, flavoring agents, and sweetening agents. The tablets may be prepared by conventional mixing, granulating or coating methods.

In addition, the parenteral administration forms may be transdermal dosage forms, and may be formulations such as injections, drops, ointments, lotions, gels, creams, sprays, suspensions, emulsions, suppositories, But is not limited thereto.

The pharmaceutical composition may be administered parenterally, rectally, topically, transdermally, subcutaneously, and the like. The pharmaceutical composition according to one embodiment of the present invention may be administered topically, for example, to the scalp.

The dosage of the active ingredient is within the level of ordinary skill in the art and the daily dose of the drug depends on various factors such as the degree of progress of the subject to be administered, the age of onset, age, health condition, Kg / day to 200 mg / kg in one aspect and 50 占 퐂 / kg to 50 mg / kg / day in one aspect, divided by 1 to 3 times a day, Method is not limited to the scope of the present invention.

The pharmaceutical composition may be an external preparation for skin, and the external preparation for skin may include any substance applied outside the skin, and may include various formulations of medicines.

According to one exemplary embodiment, the composition may be a cosmetic composition.

The cosmetic composition may further contain, in addition to the active ingredient described in the present specification, a functional additive and a component included in a general cosmetic composition. The functional additives may include water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymeric polysaccharides, sphingolipids and seaweed extracts. Examples of the other ingredients that can be included in the composition include humectants, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbents, preservatives, bactericides, antioxidants, plant extracts, pH adjusters, alcohols, Accelerators, coolants, antiperspirants, purified water, and the like.

The formulation of the cosmetic composition is not particularly limited and may be appropriately selected according to the purpose. For example, skin lotion, skin softener, skin toner, astringent, lotion, milky lotion, moisturizing lotion, nutrition lotion, massage cream, nutritional cream, moisturizing cream, hand cream, foundation, essence, nutrition essence, pack, soap, cleansing But the present invention is not limited thereto, and may be manufactured by any one or more formulations selected from the group consisting of a foam, a cleansing lotion, a cleansing cream, a body lotion and a body cleanser.

When the formulation of the present invention is a paste, cream or gel, animal fiber, plant fiber, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.

In the case of the solution or emulsion of the present invention, a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.

When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolenic derivatives or ethoxylated glycerol fatty acid esters.

According to one exemplary embodiment, the composition may be a food composition.

The food composition may be in a liquid or solid form and may be in the form of, for example, various foods, beverages, gums, tea, vitamin complexes, health supplements and the like and may be in the form of powders, granules, tablets, capsules or beverages . The food composition of each formulation may be formulated without difficulty by those skilled in the art according to the purpose of formulation or use, in addition to the effective ingredients disclosed in the present specification, and when they are simultaneously applied with other ingredients, Can happen.

There are no particular limitations on the liquid components that can be contained in addition to the active ingredients disclosed in this specification, and may include various flavoring agents or natural carbohydrates such as ordinary beverages as additional ingredients. Examples of the natural carbohydrate include common saccharides such as disaccharides such as monosaccharide, glucose and fructose, polysaccharides such as maltose and sucrose, dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol . The above flavoring agents can be advantageously used as natural flavorings (tau martin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (for example, saccharin, aspartame etc.) The ratio of the natural carbohydrate may be generally about 1 to 20 g per 100 ml of the composition disclosed herein, and about 5 to 12 g per side.

In one aspect, the food composition may contain flavors such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and heavies such as cheese and chocolate, pectic acid and its salts, alginic acid and its salts , Organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. On the other hand, flesh for the production of natural fruit juices and vegetable beverages. These components can be used independently or in combination. The proportion of the additive may vary, but is generally selected in the range of from 0.001 to about 20 parts by weight per 100 parts by weight of the composition disclosed herein.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not construed as being limited by these embodiments.

Production Examples 1. Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, Theasaponin C1, )

To 1 kg of Camellia Seed, 3 L of hexane was added, and the mixture was degassed by stirring at room temperature. Then, 4 kg of 50% ethanol was added to 0.5 kg of the defatted camellia seeds, refluxed three times and then immersed at 15 캜 for 1 day. Thereafter, the residue and filtrate were separated by filtration through a filter cloth and centrifugation, and the separated filtrate was concentrated under reduced pressure to prepare a camellia seed extract.

In addition, 7.37 g of the above-prepared camellia seed extract was suspended in water and fractionated with n-BuOH. In 2.54 g of the obtained BuOH-soluble fraction, 1.40 g was subjected to RP MPLC with 35% MeOH eluting solvent. Among them, HPCCC was performed under the condition of B4 small fraction elution solvent CMIW = 9: 6: 1: 4 (+ 0.2% acetic acid). The small fractions B41, B42, B43 and B44 thus obtained were purified according to HPLC conditions and found to be B41p1 (1.6 mg), B41p2 (Assamsaponin B, 3.9 mg), B42p1 (Theasaponin E1, 12.8 mg), B42p2 (Theasaponin E2, Eight kinds of substances were obtained (B), B43p2 (Assamsaponin H, 2.2 mg), B43p3 (Camelliasaponin B1, 1.6 mg), B44p1 (Assamsaponin D, 3 mg) and B44p2 (Theasaponin C1, 1.6 mg) Reference).

Test Example 1. Increase of expression of hair growth factor VEGF in dermal papilla cells

The vasodilatation of vascular endothelial growth factor (VEGF), which is a growth factor necessary for the movement of hair to the growth phase, is the growth factor necessary for angiogenesis. To evaluate the efficacy, the in vitro system was applied to evaluate the efficacy of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, and Theasaponin C1 derived from Camellia saponin.

For this experiment, 4 × 10 ⁵ cells of a 47-year-old male Dermal Papilla Cell (DPC) (P.11) were seeded in 12-well plates and cultured in DMEM containing 10% fetal bovine serum And cultured in DMEM (Dulbecco's modified Eagle's medium) overnight. After the cultivation, Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D and Theasaponin C1 derived from Camellia saponin were treated with 20 ppm, respectively. Theasaponin was used as a comparative example and DMSO was used as a negative control.

Twenty-four hours later, a mixed solution of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D and Theasaponin C1 derived from Camellia saponin was collected (soup collecting) and the VEGF ELISA (Vascular Endothelial Growth Factor Enzyme-Linked Immunosorbent Assay; R & D biosystems) was used to confirm the degree of VEGF expression. The results are shown in Table 1 below.

As can be seen in Table 1, there is a remarkable difference in the effect compared to the comparative example and the control group, and it can be seen that there is a remarkable difference in effect between Assamaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D and Theasaponin C1, Expression of growth factor VEGF was increased about 3 times. Therefore, it can be understood that Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, Theasaponin C1 have excellent hair growth promoting ability.

Test Example 2. Proliferation of dermal papilla cells

The keratin proteins that make up the hair are produced in hair follicle keratinocyte, which keratinocytes differentiate from the dermal papilla cells. Therefore, if the promoter of dermal papilla cells is promoted, the activity of keratinocyte differentiated therefrom can be promoted, and furthermore, the production of hair can be promoted, if the assasaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D and Theasaponin C1 promote the activity of the dermal papilla cells. Thus, the promoting effect of papillary cell activation of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D and Theasaponin C1 was evaluated as follows.

First, in this test example, human dermal papilla cells (hDPC, obtained from Professor Kwon Sang Kwon of Seoul National University) were used for cell line experiments. The cells were incubated for 24 hours in an incubator maintained at 5% CO ₂ and 37 ° C in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Gaithersburg, MD, USA) containing 10% bovine serum serum (FBS) Theasapaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D and Theasaponin C1 from Camellia saponin were treated at 20 ppm. Theasaponin was used as a comparative example and DMSO was used as a negative control.

Cell proliferative activity (%) was measured using WST-1 kit (Roche) after 24 hours from the treatment of the test substances. The results are shown in Table 2.

As shown in Table 2, the growth rate of dermal papilla cell proliferation was about 1.5 times higher than that of the control and comparison groups. This suggests that it is possible to promote the proliferation of papillary cells and to promote the activity and keratin production of keratinocyte cells more effectively, as compared with the control group.

Test Example 3. Facilitation of hair growth in human hair follicle organ

In this test example, the hair growth promoting ability in the human hair follicle organ was confirmed.

The hair follicular organ was isolated from the scalp scalp tissue of a 55-year-old male, and the hair follicle was divided into William's E medium (L-glutamine (2 mM), insulin (10 μg / ml), hydrocortisone (40 ng / ml), antibiotics %). The hair follicles grown on the third day after culturing were selected and cut into 3 mm. The treated hair follicles were treated with no drug, and the control group was Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H , Assamsaponin D, Theasaponin C1 5 ppm and Theasaponin as a comparative example, respectively. After 8 days from the treatment, length measurement and photographing were carried out. The results are shown in Table 3.

As a result, as shown in Table 3, when hair length was increased in the hair follicle, the hair growth promoting effect was superior to that of the comparative example and the control group when treated with Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D and Theasaponin C1 . Therefore, it can be seen that the effect of accelerating the hair growth in the hair follicle is excellent in the hair follicle of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D and Theasaponin C1.

Test Example 4. Inhibition of PGE2, IL-6 and IL-8 production

Human fibroblasts were inoculated into 6-well culture plates at a concentration of 1 x 10 < ⁵ > cells and cultured in a 37 ° C and 5% CO ₂ incubator for 24 hours. Theasaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, Theasaponin C1 derived from Camellia saponin, and Theasaponin as a comparative example were each treated with 500 μM of H ₂ O ₂ for 24 hours, And reacted for 48 hours. After completion of the reaction, the culture solution was collected and subjected to ELISA analysis. At this time, α-bisabolol, which is a commonly used anti-inflammatory and anti-irritant, was used as a control.

PGE2 kit was purchased from Assay Design Co., IL-6 was used from Endogen, and IL-8 was purchased from Endogen Co., and the experiment was carried out according to the method described in the manual of each company. The inhibitory effect was calculated according to the following equation (1), and the measurement results are shown in Table 4 below.

[Equation 1]

Suppression effect = {1- (test sample-control) / (H ₂ O ₂ - control)} × 100

As shown in Table 4, the production amounts of PGE2, IL-6 and IL-8, which are inflammatory mediators, were compared with the control and comparison groups by addition of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D and Theasaponin C1 And it was confirmed that it has excellent anti-inflammatory effect.

Formulation examples of compositions according to one aspect of the present invention are described below, but may be applied to various other formulations, which are not intended to be limiting but merely illustrative of the invention.

[Formulation Example 1] Shampoo

Shampoos were prepared in a conventional manner according to the composition shown in Table 5 below.

[Formulation Example 2] Rinse

Rinse was prepared according to the conventional method according to the composition shown in Table 6 below.

[Formulation Example 3] ointment

Ointment was prepared by a conventional method according to the composition shown in Table 7 below.

[Formulation Example 4] Hair tonic

Hair tonics were prepared in a conventional manner according to the composition shown in Table 8 below.

[Formulation Example 5] Hair lotion

Hair lotions were prepared in a conventional manner according to the composition shown in Table 9 below.

[Formulation Example 6] Soap

Soaps were prepared in a conventional manner according to the compositions shown in Table 10 below.

[Formulation Example 7] Lotion

Lotions were prepared in a conventional manner according to the composition shown in Table 11 below.

[Formulation Example 8] Cream

Creams were prepared in a conventional manner according to the compositions shown in Table 12 below.

[Formulation Example 9] Pack

Packs were prepared in a conventional manner according to the composition shown in Table 13 below.

[Formulation Example 10] Cosmetic liquid preparation

The cosmetic formulations were prepared in a conventional manner according to the composition shown in Table 14 below.

[Formulation Example 11] Soft capsule

Carnitine 80 mg, soybean oil 180 mg, palm oil 2 mg, vegetable hydrogenated oil 8 mg, yellowpearl 4 mg, and lecithin 6 mg, or a mixture of at least one compound selected from the group consisting of L-carnitine 80 mg, Were mixed, and 400 mg / capsule was filled according to a conventional method to prepare a soft capsule.

[Formulation Example 12] Tablets

50 mg of at least one compound selected from the group consisting of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D and Theasaponin C1, galactooligosaccharide 200 mg, lactose 60 mg and maltose 140 mg were mixed and granulated using a fluidized- 6 mg of sugar ester was added and tableted by tableting machine.

[Formulation Example 13]

50 mg of an at least one compound selected from the group consisting of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D and Theasaponin C1, 250 mg of anhydrous crystalline glucose and 550 mg of starch were mixed and granulated into granules using a fluidized- To prepare granules.

[Formulation Example 14]

50 mg of at least one compound selected from the group consisting of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D and Theasaponin C1, glucose 10 g, citric acid 0.6 g and liquid oligosaccharide 25 g were mixed and then 300 ml of purified water was added to each bottle Fill 200ml each. And then sterilized at 130 DEG C for 4 to 5 seconds to prepare a beverage drink.

Having described specific portions of the present invention in detail, it will be apparent to those skilled in the art that this specific description is only a preferred embodiment and that the scope of the present invention is not limited thereby. It will be obvious. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Claims (9)

The present invention relates to a method for producing a compound of the formula (I), which is represented by the following formula: Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D and Theasaponin C1 C1) as an active ingredient.
[Chemical Formula]

The present invention relates to a method for producing a compound of the formula (I), which is represented by the following formula: Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D and Theasaponin C1 C1) as an active ingredient.
[Chemical Formula]

3. The method according to claim 1 or 2,
Wherein the active ingredient is separated from Camellia Seed extract.
The method according to claim 1,
Wherein said composition proliferates a follicular dermal papilla cell.
3. The method of claim 2,
Wherein said composition inhibits PGE2, IL-6 or IL-8 production.
3. The method according to claim 1 or 2,
Wherein the active ingredient is included in an amount of from 0.001 to 20% by weight based on the total weight of the composition.
3. The method according to claim 1 or 2,
Wherein the composition is a pharmaceutical composition.
3. The method according to claim 1 or 2,
Wherein the composition is a cosmetic composition.
3. The method according to claim 1 or 2,
Wherein the composition is a food composition.